Adoption of total neoadjuvant therapy for locally advanced rectal cancer

JAMA Oncology

Volumn 4, Issue 6, 2018, Pages

  Cercek, Andrea ^a   Roxburgh, Campbell S D ^a,b   Strombom, Paul ^a   Smith, J Joshua ^a   Temple, Larissa K F ^a   Nash, Garrett M ^a   Guillem, Jose G ^a   Paty, Philip B ^a   Yaeger, Rona ^a   Stadler, Zsofia K ^a   Seier, Kenneth ^a   Gonen, Mithat ^a   Segal, Neil H ^a   Reidy, Diane L ^a   Varghese, Anna ^a   Shia, Jinru ^a   Vakiani, Efsevia ^a   Wu, Abraham J ^a   Crane, Christopher H ^a   Gollub, Marc J ^a   Garcia Aguilar, Julio ^a   Saltz, Leonard B ^a   Weiser, Martin R ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PREOPERATIVE CHEMOTHERAPY; PREOPERATIVE RADIOTHERAPY; RECTUM CANCER; RECTUM RESECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; ILEOSTOMY; MICROMETASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE CARE; RECTUM TUMOR; REMISSION; TUMOR INVASION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION, RADIATION; FEMALE; FLUOROURACIL; HUMANS; ILEOSTOMY; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM MICROMETASTASIS; ORGANOPLATINUM COMPOUNDS; OXALIPLATIN; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROCTECTOMY; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RECTAL NEOPLASMS; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 85049722845     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.0071     Document Type: Article

References (31)

1. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375(9719):1030-1047.
2. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24(4):668-674.
3. Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12(4):513-519.
4. Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26(8):1722-1728.
5. National Comprehensive Cancer Network. NCCN guidelines: rectal cancer. http://www.nccn.org/professionals/physician-gls/pdf/rectal.pdf. Accessed February 2, 2017. 2016.
6. Appelt AL, Ploøen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study. Lancet Oncol. 2015;16(8):919-927.
7. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11): 1465-1471.
8. Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33(32):3733-3740.
9. Schmoll HJ, Twelves C, Sun W, et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: A pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol. 2014;15(13):1481-1492.
10. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29 (28):3768-3774.
11. Smith JJ, Chow OS, Eaton A, et al. Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy. J Clin Oncol. 2015;33(Suppl. 3):abstr. 509.
12. Trakarnsanga A, Gönen M, Shia J, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst. 2014; 106(10):dju248.
13. Washington MK, Berlin J, Branton P, et al; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133(10):1539-1551.
14. Habr-Gama A, Perez RO, NadalinW, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4): 711-717.
15. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53(12): 1692-1698.
16. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633-4640.
17. R Core Team. R: A language and environment for statistical computing, 2014. http://www.R-project.org. Accessed July 5, 2017.
18. Nogué M, Salud A, Vicente P, et al; AVACROSS Study Group. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16(5): 614-620.
19. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859-865.
20. Garcia-Aguilar J, Chow OS, Smith DD, et al; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: A multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957-966.
21. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase 2 trial. Lancet Oncol. 2010;11(3):241-248.
22. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20): 2773-2780.
23. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558-4565.
24. Rödel C, Graeven U, Fietkau R, et al; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979-989.
25. Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256(6):965-972.
26. Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2): 174-183.
27. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10(10):1319-1328.
28. Smith JJ, Chow OS, Gollub MJ, et al; Rectal Cancer Consortium. Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.
29. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71(4):1181-1188.
30. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582-589.
31. Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113(1): 57-64.